What a Physician-Epidemiologist Tells Friends and Family About Living Longer

Read Time: 5 min

I have spent my career studying how diseases spread through populations, how public health systems succeed or fail at preventing them, and what the evidence actually says about why some people live longer than others. That background shapes how I respond when friends and family ask me what they should be doing to live a longer and healthier life — a question that has become considerably more complicated to answer now that the longevity industry has saturated the media environment with expensive, heavily marketed, and frequently under-evidenced alternatives to the guidance that public health and medical research have been refining for decades.

My answer, when stripped of commercial incentive and grounded in what the medical and public health literature consistently supports, is genuinely unglamorous. Keep your BMI between 18.5 and 24.9. Exercise every day. Avoid cigarettes entirely. Limit alcohol consumption. These recommendations appear repeatedly across large, well-designed studies in diverse populations, and their effect sizes are substantial — not the marginal, speculative, or preliminary effects that characterize much of what the longevity industry sells, but robust associations with meaningful reductions in mortality from the leading causes of death.

Why Clinical Care Still Matters, and Where Its Limits Are

Acknowledging the primacy of these behavioral and social factors in determining longevity is entirely compatible with valuing clinical medicine, which remains genuinely life-saving for people with underlying diseases and health conditions. The framing that pits public health against clinical care is a false one; both are necessary, and the evidence supports a clear view of where each contributes most. For people managing diabetes, high blood pressure, asthma, HIV, and many other chronic conditions, access to high-quality medical care is the difference between controlled disease and preventable death, and too many Americans still lack adequate access to that care despite living in the wealthiest country in human history.

Cancer screening occupies a specific and evidence-supported place in this picture. I recommend that adults be screened for breast, cervical, and colon cancer because the evidence from large, well-designed trials demonstrates clearly that early detection improves both how long people live and how well they live during those years. These programs represent clinical medicine at its most effective — targeted, evidence-driven, population-scaled, and accessible through the regular healthcare system rather than available only to those who can afford a $500,000 annual retainer.

The distinction I draw is between interventions with that kind of evidence base and the expanding universe of personalized longevity services that charge substantial sums for blood panels, imaging studies, and prescriptions that run well ahead of what the published science supports for healthy people without specific risk factors. The existence of a test or a service on the market, offered by a credentialed physician, carries no guarantee that it has been validated in the populations where it is being used, or that its benefits outweigh the harms of false positives, unnecessary follow-up, and the anxiety that often accompanies results that are ambiguous rather than actionable.

The Longevity Factors That Cannot Be Purchased

The most honest conversation I can have with someone who wants to live longer requires acknowledging something the longevity industry rarely says directly: the factors with the strongest evidence behind them are largely structural, not individual. Educational attainment is among the most powerful predictors of life expectancy in high-income countries. Income shapes longevity through housing quality, neighborhood conditions, access to nutritious food, and the chronic physiological burden of financial stress. Living in a community with lower air pollution and fewer traffic accidents extends lives in measurable ways that accumulate over decades.

These are observations about structural conditions, and I raise them with the full recognition that not everyone has equal access to the educational and economic opportunities that correlate with longer lives. That inequality is itself a public health problem, one that requires policy responses operating at a scale that is entirely beyond the reach of any individual consumer decision. Telling someone to get a good education and a decent income as longevity advice is both scientifically accurate and socially incomplete if it is offered without acknowledgment that the distribution of those opportunities in the United States remains profoundly unequal.

What I find most clarifying about the current longevity conversation is the contrast between where the commercial attention goes and where the evidence points. The industry directs energy and capital toward expensive, personalized, high-tech interventions with preliminary or contested evidence bases. The evidence directs attention toward clean air and water, economic security, equitable access to education, and the behavioral fundamentals — exercise, not smoking, moderate alcohol — that have been supported by decades of rigorous research. One of those sets of priorities is good for business. The other is good for public health. Recognizing the difference is, I think, one of the most practically useful things any of us can do for our own longevity.